This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Additional contraceptive precautions if stopped hepatic enzyme inducer but continue combined oral contraceptive (COC) pill

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • enzyme inducers and the combined pill
    • enzyme activity does not return to normal for several weeks after stopping an enzyme-inducing drug - therefore appropriate contraceptive measures are required for 4 weeks for the liver enzymes to return to normal functionality (1)

      • therefore higher doses of the COC, with or without additional contraceptive protection, should be continued for 4 weeks after stopping the AED (2)

        • this period should be increased to 8 weeks after more prolonged used of enzyme inducers. In all cases, the PFI should be omitted when switching back to a standard or low-dose COC (2)

Reference:

  1. Faculty of Sexual & Reproductive Healthcare Clinical Guidance.Clinical Guidance: Drug Interactions with Hormonal Contraception January 2018.
  2. NHS Specialist Pharmacy Service (May 2019). Which combined oral contraceptive pill is suitable in a patient who is taking hepatic enzyme-inducing drugs, such as carbamazepine, phenytoin, rifampicin or rifabutin?

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.